Clinical Trials Logo

Substance Withdrawal clinical trials

View clinical trials related to Substance Withdrawal.

Filter by:
  • None
  • Page 1

NCT ID: NCT06223191 Enrolling by invitation - Clinical trials for Substance Use Disorders

Reducing Readmissions: BNI Trial in Substance Use Disorder

Start date: January 29, 2024
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to assess the effectiveness of Brief Negotiated Interview (BNI) in comparison to Narrative Therapy and Standard Care in reducing readmissions among male patients aged 18 and above with a history of substance use disorder The main questions it aims to answer is: Does the Brief Negotiated Interview reduces rehospitalization rates at least to 50%? Participants will be submitted to a Structured interview with motivational interviewing techniques. Researchers will compare 2 control groups one with standards of care and the other one with a narrative interview to see if they reduce readmission.

NCT ID: NCT04556552 Completed - Opioid Use Clinical Trials

Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders

nVNS in OUDs
Start date: November 13, 2020
Phase: Phase 3
Study type: Interventional

Subjects in this study will be patients with opioid use disorders (OUDs) based on DSM-5 criteria recruited from the greater Atlanta metropolitan region. Recruitment will be from treatment programs in the greater Atlanta Metropolitan Region including the DeKalb Community Service Board residential, detoxification and other treatment programs which with over 30,000 patient visits per year represents the largest treatment program in one of two urban counties in greater Atlanta. This trial involves a second phase after completing an exploratory study in 20 patients with OUDs to assess different timing parameters of nVNS effects on sympathetic measures and symptoms of craving, as well as modelling to verify and iteratively refine the methods for vagal nerve stimulation. The investigators in this trial will then apply nVNS comparing active (N=10) to sham (N=10) in OUD patients recently started on medication, looking at opioid craving, brain functional response with HR-PET, and cardiovascular and inflammatory biomarker responses to imagery-induced opioid drug craving.